GE HealthCare Misses Q1 Earnings on Supply Chain Issues, Cuts Full-Year Profit Outlook
GE HealthCare (NASDAQ: GEHC) reported first-quarter 2026 earnings that fell short of expectations, with adjusted earnings per share of $0.99 missing consensus estimates as supply chain disruptions and rising inflation pressured margins. The medical technology giant cut its full-year profit outlook while maintaining revenue guidance, citing healthy global demand for its imaging and diagnostic products.
Key Numbers
The company reported diluted earnings per share of $0.85, down 31% from $1.23 in the prior year period. On an adjusted basis, EPS came in at $0.99, down from $1.01 a year ago and below analyst expectations. The miss was driven by a 420 basis point decline in net income margin to 7.6%, while adjusted EBIT margin fell 150 basis points to 13.5%.
Revenue grew 7.4% to $5.1 billion, with organic growth of 2.9% meeting the high end of management's expectations. The Pharmaceutical Diagnostics segment led growth with a 21.7% revenue increase, driven by strong demand for the company's Flyrcado cardiac imaging agent. Advanced Visualization Solutions revenue rose 8.2%, while Imaging grew 7.4%. Patient Care Solutions was the lone decliner, falling 6.5%.
Order growth slowed significantly to 1.1% organically, compared to 10.3% growth in the year-ago period. The company maintained a healthy book-to-bill ratio of 1.07 times and a backlog of $21.8 billion, indicating steady demand despite the slowdown.
Cash flow from operations improved to $290 million from $250 million a year ago, while free cash flow rose modestly to $112 million from $99 million.
What Management Said
CEO Peter Arduini acknowledged the challenging quarter while emphasizing strong underlying demand. "Profitability in the first quarter was impacted by a PDx supplier issue that has since been resolved," Arduini stated in the earnings release. He noted that "significant increases in memory chips, oil and freight costs during the first quarter" would likely impact results for the remainder of 2026.
Despite the headwinds, management struck an optimistic tone about the company's ability to navigate the challenges. "We are taking a prudent approach and reducing our profit outlook but expect to offset more than half of the inflation impact with price and cost actions," Arduini explained.
The CEO also highlighted progress on the company's innovation pipeline, stating they are "making meaningful progress executing on our new wave of innovation to accelerate future revenue and margin growth." This includes recent FDA clearances for next-generation MRI technology and the Photonova Spectra photon-counting CT system.
What to Watch
GE HealthCare's revised full-year 2026 guidance reflects both the supply chain challenges and inflationary pressures impacting the business. The company maintained its organic revenue growth outlook of 3-4% but cut its adjusted EBIT margin guidance to 15.4-15.7% from the previous 15.8-16.1%. Adjusted EPS guidance was reduced to $4.80-$5.00 from $4.95-$5.15, representing growth of just 4.6-9.0% versus the prior year.
Free cash flow guidance was lowered to approximately $1.6 billion from $1.7 billion, aligning with the reduced profit outlook.
Investors should monitor several key developments in coming quarters. First, the resolution of the Pharmaceutical Diagnostics supplier issue should remove a headwind, though rising input costs for memory chips, oil, and freight remain concerns. The company's ability to implement pricing actions to offset these costs will be critical for margin recovery.
Second, the $2.3 billion acquisition of Intelerad, completed during the quarter, represents a significant bet on cloud-enabled enterprise imaging solutions. Integration progress and revenue synergies from this deal will be important to track.
Third, the innovation pipeline shows promise with multiple FDA clearances and new product launches. The commercial success of products like Flyrcado and the new SIGNA MRI technology could drive future growth acceleration.
Finally, the significant deceleration in order growth from 10.3% to 1.1% warrants attention. While the company maintains a healthy backlog, sustained weakness in orders could signal softer demand ahead.
The company faces a challenging environment with multiple crosscurrents. While underlying demand remains healthy and the innovation pipeline is robust, near-term margin pressure from inflation and supply chain issues has forced management to reset expectations. Successful execution on pricing initiatives and cost controls will determine whether GE HealthCare can deliver on its revised targets for the remainder of 2026.
*Source: GE HealthCare Q1 2026 Earnings Report*
— StockCliff Research